Welcome
Support Centre
02 September 2010 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Amniocentesis Results: Investigation of Anxiety
Source of recordUK Trials
ISRCTNISRCTN54376052
Date ISRCTN assigned17/10/2002
Local reference number(s)HTA 99/48/04
Public titleAmniocentesis Results: Investigation of Anxiety
Scientific title
AcronymARIA
Disease/condition/study domainPregnancy
Study hypothesisThere is evidence both that being able to predict stressful events, and having information which normalises the content and timing of worries about such events, reduces anxiety. This provides scope for interventions designed to minimise anxiety while waiting for test results.

Phase one:
1. To identify patterns of anxiety and the factors that contribute to this.
2. To develop an appropriate intervention for phase two, the RCT. 3. To obtain information about the patterns of anxiety which will inform the outcome measures and the timing of measurement in the RCT.

Phase two - to test the following hypotheses:
1.That giving amniocentesis results out on a fixed date with an undertaking not to phone earlier even if possible, alters maternal anxiety during the waiting period, compared with a policy of phoning as soon as possible.
2. Providing parents with a "debriefing" leaflet describing the normal pattern of worry during the waiting period, reduces anxiety.
Design/methodology2 X 2 factorial design randomised controlled trial
Research ethics reviewNot provided at time of registration
Countries of trialUnited Kingdom
Participants - inclusion criteriaPregnant women who are having an amniocentesis for indications such as maternal age, triple test risk or the presence of a soft marker for Downs Syndrome
Participants - exclusion criteriaWomen with a major structural abnormality on scan. Women who miscarry before the karyotype result is obtained (<1%) or whose result indicates aneuploidy (1 in 70) will be excluded from the primary analysis.
Patient information material
Anticipated start date01/09/2001
Anticipated end date31/03/2005
Status of trialCompleted
Target number of participants226
InterventionsPlease note that, as of 15 January 2008, the start and end dates of this trial have been updated from 1 January 2001 and 31 December 2003 to 1 September 2001 and 31 March 2005, respectively.

Interventions:
Phase one: an observational cohort study (n=30) using anxiety diaries and qualitative interviews. Phase two: a 2 X 2 factorial design randomised controlled trial. Participants will be randomised immediately after amniocentesis to "phone result when available" or "issue result on a fixed date" and to "leaflet" or "no leaflet". The trial will use independent telephone randomisation, stratified by centre and maternal age (<35, >=35years). Setting: seven amniocentesis clinics = Leeds General Infirmary and St James's, Airedale, Harrogate, York, Hull Maternity Hospital and Castle Hill.
The aim is to investigate how two interventions, firstly, the issue of a standard culture result on a fixed date (18 days after amniocentesis) or variable date, secondly, how the implementation of a new cytogenetic technique, Fluorescent In-situ Hybridisation (FISH), affect maternal anxiety levels.
Primary outcome measure(s)We will measure anxiety daily using the short Spielberger state measure with regular phone reminders The primary outcomes will be total anxiety in the first 24 hours after the test, over the last 24 hours before the result is issued, and the peak level of anxiety reached. Within 24 hours of issuing the results, parents will be asked to recall and score their anxiety over the waiting period. This will provide validation of the prospectively collected scores. We will not conduct any economic analysis because the costs of different modes of issuing results will be similar and the leaflets will be cheap. We will recommend that the method, which minimises anxiety, be used.
Secondary outcome measure(s)Not provided at time of registration
Trial websitehttp://www.leeds.ac.uk/medicine/psychiatry/research/aria.htm
PublicationsHTA monograph published, see http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17134598
Sources of fundingNIHR Health Technology Assessment Programme - HTA (UK)
Sponsor nameDepartment of Health (UK)
Sponsor detailsQuarry House
Quarry Hill
Leeds
United Kingdom
LS2 7UE
Sponsor emailSheila.Greener@doh.gsi.gov.uk
Sponsor websitehttp://www.dh.gov.uk/en/index.htm
Contact nameProf Jenny Hewison
Contact detailsAcademic Department of Psychiatry and Behavioural Sciences
University of Leeds
15 Hyde Terrace
Leeds
United Kingdom
LS2 9LT
Contact telephone+44 (0)113 343 1894
Contact fax+44 (0)113 243 3719
Contact emailj.hewison@leeds.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN54376052
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central